{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:50:40Z","timestamp":1790481040023,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.pcl.2005.02.009","type":"journal-article","created":{"date-parts":[[2005,7,6]],"date-time":"2005-07-06T21:13:22Z","timestamp":1120684402000},"page":"895-915","source":"Crossref","is-referenced-by-count":45,"title":["Antifungal Agents in Children"],"prefix":"10.1016","volume":"52","author":[{"given":"William J.","family":"Steinbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2005.02.009_bib1","doi-asserted-by":"crossref","first-page":"133S","DOI":"10.1592\/phco.21.12.133S.34507","article-title":"Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo","volume":"21","author":"Groll","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pcl.2005.02.009_bib2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/infdis\/152.5.1037","article-title":"Distribution and activity of amphotericin B in humans","volume":"152","author":"Christensen","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/clinids\/12.6.1147","article-title":"Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases","volume":"12","author":"Denning","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1399-3062.2000.020203.x","article-title":"Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?","volume":"2","author":"Ellis","year":"2000","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0030-6665(00)80005-5","article-title":"Agents for treatment of invasive fungal infections","volume":"33","author":"Luna","year":"2000","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.pcl.2005.02.009_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0924-8579(00)00221-1","article-title":"New antifungal agents and preparations","volume":"16","author":"de Pauw","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pcl.2005.02.009_bib7","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib8","doi-asserted-by":"crossref","first-page":"S501","DOI":"10.1093\/clinids\/17.Supplement_2.S501","article-title":"New methods of delivery of amphotericin B","volume":"17","author":"Schmitt","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.38.2.223","article-title":"Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B","volume":"38","author":"Wasan","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/313748","article-title":"Introduction to antifungal agents","volume":"30","author":"Dismukes","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/28.suppl_B.49","article-title":"Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents","volume":"28","author":"Proffitt","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficiacy and toxicities","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0272-6386(98)70046-0","article-title":"Renal effects of amphotericin B lipid complex","volume":"31","author":"Luke","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib14","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerate dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children","volume":"22","author":"Sandler","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.pcl.2005.02.009_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00006454-199908000-00010","article-title":"Amphotericin B lipid complex in pediatric patients with invasive fungal infections","volume":"18","author":"Walsh","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2005.02.009_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-2007-994083","article-title":"Liposomal amphotericin B in neonates with invasive candidiasis","volume":"15","author":"Al Arishi","year":"1998","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.pcl.2005.02.009_bib18","series-title":"Focus on fungal infections 14","article-title":"Safety and efficacy of ambisome in patients with fungal infections: a post marketing multicentre surveillance study in Turkey","author":"Anak","year":"2004"},{"key":"10.1016\/j.pcl.2005.02.009_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/mmy.38.s1.323.333","article-title":"Antifungal compounds: controversies, queries and conclusions","volume":"38","author":"Graybill","year":"2000","journal-title":"Med Mycol"},{"key":"10.1016\/j.pcl.2005.02.009_bib21","first-page":"1","article-title":"Lipid formulations of amphotericin B","volume":"20","author":"Dix","year":"2000","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib22","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jac\/dkg419","article-title":"Treatment of candidaemia in premature infants: comparison of three amphotericin B products","volume":"52","author":"Linder","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100960000437","article-title":"Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunocompromised paediatric patients","volume":"20","author":"Herbrecht","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00006454-199802000-00013","article-title":"Liposomal amphotericin B treatment for neonatal fungal infections","volume":"17","author":"Scarcella","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2005.02.009_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02768745","article-title":"Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome)","volume":"26","author":"Weitkamp","year":"1998","journal-title":"Infection"},{"key":"10.1016\/j.pcl.2005.02.009_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-003-0993-4","article-title":"High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates","volume":"22","author":"Juster-Reicher","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s150100070040","article-title":"Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birthweight infants","volume":"28","author":"Juster-Reicher","year":"2000","journal-title":"Infection"},{"key":"10.1016\/j.pcl.2005.02.009_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-86-3-319","article-title":"Flucytosine","volume":"86","author":"Bennett","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1445-5994.1974.tb03218.x","article-title":"Therapy of deep-seated fungal infections with 5-fluorocytosine","volume":"4","author":"Firkin","year":"1974","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00005792-197003000-00002","article-title":"Aspergillosis: the spectrum of the disease in 98 patients","volume":"49","author":"Young","year":"1970","journal-title":"Medicine"},{"key":"10.1016\/j.pcl.2005.02.009_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/28.suppl_B.27","article-title":"Amphotericin B: an introduction","volume":"28","author":"Warnock","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.14.6.903","article-title":"Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity","volume":"14","author":"Diasio","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJM198708063170602","article-title":"Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks","volume":"317","author":"Dismukes","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","article-title":"Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America","volume":"30","author":"Saag","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/clinids\/6.6.791","article-title":"Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis","volume":"6","author":"Smego","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/mmy.38.s1.335.347","article-title":"New targets and delivery systems for antifungal therapy","volume":"38","author":"Walsh","year":"2000","journal-title":"Med Mycol"},{"key":"10.1016\/j.pcl.2005.02.009_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","article-title":"Pharmacology of itraconazole","volume":"61","author":"De Beule","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.pcl.2005.02.009_bib43","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1128\/AAC.41.6.1392","article-title":"Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans","volume":"41","author":"Klepser","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01974613","article-title":"Pharmacokinetics of fluconazole in pediatric patients","volume":"13","author":"Brammer","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1439-0507.1997.tb00230.x","article-title":"Fluconazole: comparison of pharmacokinetics, therapy, and in vitro susceptibility","volume":"40","author":"Wildfeuer","year":"1997","journal-title":"Mycoses"},{"key":"10.1016\/j.pcl.2005.02.009_bib46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pcl.2005.02.009_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/AAC.35.2.365","article-title":"Fluconazole in the treatment of candidiasis in immunocompromised children","volume":"35","author":"Vscoli","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib48","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.43.8.1955","article-title":"Safety and tolerability of fluconazole in children","volume":"43","author":"Novelli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib49","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pcl.2005.02.009_bib50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole + placebo vs. fluconazole + amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib51","first-page":"325","article-title":"Fluconazole treament of neonates and infants with severe fungal infections not treatable with conventional agents","volume":"13","author":"Fasano","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib52","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/00006454-199811000-00010","article-title":"Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis","volume":"17","author":"Huttova","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2005.02.009_bib53","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/00006454-199612000-00011","article-title":"Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial","volume":"15","author":"Driessen","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2005.02.009_bib54","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2005.02.009_bib55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.10234","article-title":"Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation","volume":"71","author":"Koh","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pcl.2005.02.009_bib56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9343(01)01127-5","article-title":"Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenace therapy","volume":"112","author":"MacMillan","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib57","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMoa010494","article-title":"Fluconazole prophylaxis against fungal colonization and infection in preterm infants","volume":"345","author":"Kaufman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib58","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependent fungicidal activity of azoles","volume":"42","author":"Manavathu","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib59","first-page":"7","article-title":"Itraconazole","volume":"35","author":"Anonymous","year":"1993","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.pcl.2005.02.009_bib60","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.42.2.404","article-title":"Repeated-dose pharmacokinetic of an oral solution of itraconazole in infants and children","volume":"42","author":"de Repentigny","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib61","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/AAC.45.5.1561-1564.2001","article-title":"Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis","volume":"45","author":"Schmitt","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib62","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.46.8.2554-2563.2002","article-title":"Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis","volume":"46","author":"Groll","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/jac\/26.4.561","article-title":"Adverse events associated with itraconazole in 189 patients on chronic therapy","volume":"26","author":"Tucker","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib64","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophoshamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2005.02.009_bib65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2133.1999.00011.x","article-title":"Drug interactions of the newer oral antifungal agents","volume":"141","author":"Katz","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pcl.2005.02.009_bib66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies","volume":"105","author":"Morgenstern","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pcl.2005.02.009_bib67","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00007890-200209150-00017","article-title":"Randomized controlled trial of oral itraconazole solution versus intravenous\/oral fluconazole for prevention of fungal infections in liver transplant recipients","volume":"74","author":"Winston","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.pcl.2005.02.009_bib68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/338154","article-title":"A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients wiht advanced human immunodeficiency virus infection in Thailand","volume":"34","author":"Chariyalertsak","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib69","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: a new triazole antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pcl.2005.02.009_bib70","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/42.6.741","article-title":"In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi","volume":"42","author":"Johnson","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/46.2.229","article-title":"A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)","volume":"46","author":"Manavathu","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib72","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00008571-199412000-00001","article-title":"Biochemistry and molecular biology of the human CYP2C subfamily","volume":"4","author":"Goldstein","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pcl.2005.02.009_bib74","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib75","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib76","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0091270002424005","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pcl.2005.02.009_bib77","unstructured":"Stone J., Holland S., Li S., et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2001. Abstract A-14. p. 45"},{"key":"10.1016\/j.pcl.2005.02.009_bib78","unstructured":"Tan K.K.C., Brayshaw N., Oakes M. Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials. In: Program and abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001. Abstract A-18. p. 46"},{"key":"10.1016\/j.pcl.2005.02.009_bib79","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1365-2230.2001.00909.x","article-title":"Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole","volume":"26","author":"Denning","year":"2001","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.pcl.2005.02.009_bib80","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","article-title":"Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes","volume":"46","author":"Venkataramanan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib81","unstructured":"Wood N., Tan K., Allan R., Fielding A., Nichols D.J. Effect of voriconazole on pharmacokinetics of tacrolimus. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001. Abstract A-20"},{"key":"10.1016\/j.pcl.2005.02.009_bib82","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib84","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocumpromised patients","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib85","unstructured":"Kullberg B.J. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment of candidaemia in non-neutropenic patients. In: 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic, 2004. Abstract 10.111"},{"key":"10.1016\/j.pcl.2005.02.009_bib86","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib87","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2005.02.009_bib88","doi-asserted-by":"crossref","first-page":"165S","DOI":"10.1592\/phco.21.12.165S.34509","article-title":"Investigational antifungal agents","volume":"21","author":"Ernst","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pcl.2005.02.009_bib89","unstructured":"Hachem R.Y., Raad I.I., Afif C.M., et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, 2000. Abstract 1109"},{"key":"10.1016\/j.pcl.2005.02.009_bib90","unstructured":"Segal B.H., Barnhart L.A., Anderson V.L., Malech H.L. Posaconazole in salvage therapy in patients with chronic granulomatous disease with invasive fungal infections. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003. Abstract M-1756"},{"key":"10.1016\/j.pcl.2005.02.009_bib91","unstructured":"Greenberg R.N., Anstead G., Herbrecht R., et al. Posaconazole experience in the treatment of zygomycosis. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2003. Abstract M-1757"},{"key":"10.1016\/j.pcl.2005.02.009_bib92","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/AAC.44.2.441-443.2000","article-title":"In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B","volume":"44","author":"Moore","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib93","first-page":"555","article-title":"Ravuconazole","volume":"3","author":"Arikan","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.pcl.2005.02.009_bib94","unstructured":"Olsen S.J., Mummaneni V., Rolan P., Norton J., Grasela D.M. Ravuconazole single ascending oral dose study in healthy subjects. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, 2000. Abstract 838"},{"key":"10.1016\/j.pcl.2005.02.009_bib95","unstructured":"Beale M., Queiroz-Telles F., Banhegyi D., Li N., Pierce P.F. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001. Abstract J-1621"},{"key":"10.1016\/j.pcl.2005.02.009_bib96","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.41.11.2326","article-title":"In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)","volume":"41","author":"Bartizal","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/02681219780000961","article-title":"Lipopeptide inhibitors of fungal glucan synthase","volume":"35","author":"Kurtz","year":"1997","journal-title":"J Med Vet Mycol"},{"key":"10.1016\/j.pcl.2005.02.009_bib98","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1742-1241.2001.tb11144.x","article-title":"The echinocandins, first novel class of antifungals in two decades: will they live up to their promise?","volume":"55","author":"Graybill","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pcl.2005.02.009_bib99","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1128\/AAC.45.2.596-600.2001","article-title":"Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1634\/theoncologist.5-2-120","article-title":"New drugs and novel targets for treatment of invasive fungal infections in patients with cancer","volume":"5","author":"Chiou","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.pcl.2005.02.009_bib102","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1128\/AAC.41.11.2339","article-title":"Preliminary animal pharmokinetics of the parenteral antifungal agent MK-0991 (L-743,872)","volume":"41","author":"Hajdu","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib103","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","article-title":"Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis","volume":"41","author":"Abruzzo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0149-2918(02)85039-1","article-title":"Caspofungin: an echinocandin antifungal agent","volume":"24","author":"Stone","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.pcl.2005.02.009_bib105","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ajhp\/58.13.1206","article-title":"Caspofungin acetate: an antifungal agent","volume":"58","author":"Hoang","year":"2001","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.pcl.2005.02.009_bib106","unstructured":"Walsh T.J., Adamson P.C., Seibel N.L., et al. Pharmacokinetics of caspofungin in pediatric patients. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002. Abstract M-896"},{"key":"10.1016\/j.pcl.2005.02.009_bib107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of caspofungin acetate in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib108","unstructured":"Stone J., Holland S., Wickersham P., et al. Drug interactions between caspofungin and tacrolimus. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001. Abstract A-13"},{"key":"10.1016\/j.pcl.2005.02.009_bib109","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2165\/00003495-200161080-00007","article-title":"Caspofungin","volume":"61","author":"Keating","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.pcl.2005.02.009_bib110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.inf.0000078164.80233.14","article-title":"Retrospective study of the safety of caspofungin in immunocompromised pediatric patients","volume":"22","author":"Franklin","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pcl.2005.02.009_bib111","unstructured":"Maertens J., Raad I., Sable C., et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin, amphotericin B lipid formulations, or azoles. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, 2000. Abstract J-1103"},{"issue":"11","key":"10.1016\/j.pcl.2005.02.009_bib112","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib113","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib114","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcl.2005.02.009_bib115","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/46.3.485","article-title":"In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide","volume":"46","author":"Mikamo","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib116","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7164\/antibiotics.55.219","article-title":"Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus","volume":"55","author":"Hatano","year":"2002","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pcl.2005.02.009_bib117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","article-title":"In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi","volume":"44","author":"Tawara","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib118","unstructured":"Heresi G.P., Gerstmann D.R., Blumer J.L., et al. Pharmacokinetic study of micafungin in premature neonates. Presented at: Pediatric Academic Society Meeting. Seattle, 2003. Abstract 83"},{"key":"10.1016\/j.pcl.2005.02.009_bib119","unstructured":"Ratanatharathorn V., Flynn P., Van Burik J.A., McSweeney P., Niederwieser D., Kontoyannis D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. In: Program and abstracts of the American Society of Hematology 44th Annual Meeting. Philadelphia, 2002. Abstract 2472"},{"key":"10.1016\/j.pcl.2005.02.009_bib120","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2005.02.009_bib121","unstructured":"Suleiman J., Della Negra M., Llanos-Cuentas A., Ticona E., Rex J.H., Buell D.N. Open label study of micafungin in the treatment of esophageal candidiasis. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002. Abstract M-892"},{"key":"10.1016\/j.pcl.2005.02.009_bib122","unstructured":"Ullmann A.J., Van Burik J.A., McSweeney P., et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis in adults and children. In: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, UK, 2003. Abstract O-400"},{"key":"10.1016\/j.pcl.2005.02.009_bib123","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.41.4.863","article-title":"In vitro activity of a new semisynthetic echinocandin, LY-303366, against syemstic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species","volume":"41","author":"Zhanel","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib124","unstructured":"Lucas R., De Sante K., Hatcher B., et al. LY303366 single dose pharmacokinetics and safety in healthy volunteers. In: Program and abstracts of the 36th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996. Abstract F-50"},{"key":"10.1016\/j.pcl.2005.02.009_bib125","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1128\/AAC.42.11.2898","article-title":"Antifungal efficacy, safety, and single-dose pharmokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits","volume":"42","author":"Petraitis","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pcl.2005.02.009_bib126","unstructured":"Thye D., Marbury T., Kilfoil G., Henkel T. Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. In: Program and abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002. Abstract A-1390"},{"key":"10.1016\/j.pcl.2005.02.009_bib127","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395505000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395505000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T18:04:13Z","timestamp":1683137053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395505000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0031395505000362"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2005.02.009","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}